AXSM vs UNH

Axsome Therapeutics maintains its strong trajectory, slightly improving its score due to the increased proximity of the pivotal AXS-05 (Auvelity for Alzheimer's agitation) PDUFA date on April 30, 2026, which substantially de-risks a major growth catalyst. Robust commercial execution for Auvelity (68% YoY growth) and Sunosi (40% YoY growth) continues to drive revenue (66% YoY overall). While profit...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...